Specifica Announces Antibody Discovery Platform Transfer Agreement with Servier and its Subsidiary Symphogen
Thermo Fisher Scientific and Symphogen, an affiliate of the antibody center of excellence within the international pharmaceutical company Servier, have extended their collaboration to provide biopharmaceutical discovery and development laboratories for efficient characterization of complex therapeutic proteins.
Thermo Fisher Scientific and Symphogen, an affiliate of Servier, have extended a strategic collaboration to deliver innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.
Thermo Fisher Scientific and Symphogen, an affiliate of Servier, have extended a strategic collaboration to deliver innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.
Symphogen, a Danish biotechnology company specializing in the research and development of monoclonal antibodies, becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.